Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel
20 oct. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
14 oct. 2020 17h05 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
10 sept. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
09 sept. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update
12 août 2020 16h01 HE
|
Neoleukin Therapeutics, Inc.
NL-201 IND submission anticipated during fourth quarter of 2020Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023Company to...
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
06 août 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020
05 août 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering
02 juil. 2020 09h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Proposed Public Offering
01 juil. 2020 16h01 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
22 juin 2020 09h05 HE
|
Neoleukin Therapeutics, Inc.
- NL-201 demonstrates durable antitumor activity in animal tumor models -- NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo -- Conditional activation of de novo...